Chemotherapy Dose Density in Early‐Stage Breast Cancer and Non‐Hodgkin's Lymphoma

Goldspiel, Barry R.

doi:10.1592/phco.24.14.1347.43154

Cited by 11 publications

(6 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taxanes serve as antineoplastic agents with broad antitumor activity that inhibit the functioning of microtubules, inducing altered mitosis and cellular death . They are prescribed in the management and treatment of squamous cell carcinomas of the head and neck; Kaposi sarcoma; and other cancers of the esophagus, breast, lung, stomach, bladder, prostate, and ovary . Despite their widespread use, taxanes produce several common and serious adverse events.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events

2018

View full text Add to dashboard Cite

IMPORTANCE Chemotherapy-induced alopecia as well as nail and cutaneous changes occur in up to 89% of patients receiving taxane-based chemotherapy and are associated with cosmetic concerns, psychosocial distress, and overall morbidity.OBJECTIVE To review the efficacy and safety of interventions to prevent taxane-induced dermatologic adverse events.EVIDENCE REVIEW PubMed and Scopus databases were systematically reviewed for studies published in the English language from January 1, 1980, to August 13, 2018. Specific search terms included but were not limited to taxane, docetaxel, paclitaxel, prevent, nail, skin, hair, alopecia, and onycholysis. Primary clinical studies that detailed preventive interventions for taxane-induced dermatologic adverse events and that classified results according to a taxane-specific chemotherapy regimen were reviewed and graded according to a 5-point scale, modified from the Oxford Centre for Evidence-based Medicine.FINDINGS The 34 original reports that met the inclusion criteria consisted of 6 randomized clinical trials, 4 nonrandomized clinical trials, 18 cohort studies, 3 case-control studies, 1 cross-sectional study, and 2 case reports and involved a total of 5647 unique participants. A total of 22 studies addressed preventive interventions for alopecia associated with taxane use, whereas 12 studies focused on taxane-induced skin and nail changes. Specifically, 20 (95%) of 21 studies supported the use of either a cold cap or a scalp cooling system to reduce alopecia but reported substantial differences in efficacy depending on the chemotherapy regimen. Scalp cooling was generally considered safe by all pertinent studies despite a single report of scalp skin metastasis. Similarly, use of frozen gloves and frozen socks in the prevention of nail and cutaneous hand and foot toxic effects was considered safe in 7 (88%) of 8 studies, although discomfort was common and frostbite was noted in 1 patient. Overall, use of frozen gloves was endorsed by 4 (67%) of 6 studies to prevent nail toxic effects and by 3 (60%) of 5 studies to prevent cutaneous hand changes.CONCLUSIONS AND RELEVANCE Scalp hypothermia with cold caps or scalp cooling systems has demonstrated efficacy as a monotherapy in preventing taxane-induced alopecia, and use of frozen gloves and socks has been associated with reduced nail and skin changes. Future studies should establish the routine usage protocols, standard outcome measures, and long-term efficacy and safety for these interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events

2018

View full text Add to dashboard Cite

show abstract

“…However, surgical resection is only applicable for patients at the early stage of cancer without dissemination, while chemotherapeutic drugs become the preferred treatment in advanced stages or for recurrent cancer [4]. Among the chemotherapeutic agents, paclitaxel (PTX), which obstructs cells in the late G2 phase and M phase of the cell cycle [5,6], has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ovarian cancer [7,8]. However, PTX has two main disadvantages that limit its clinical application.…”

Section: Introductionmentioning

confidence: 99%

Folate modified nanoparticles for targeted co-delivery chemotherapeutic drugs and imaging probes for ovarian cancer

Wang

et al. 2015

Biomed. Phys. Eng. Express

View full text Add to dashboard Cite

Ovarian cancer has been the leading cause of death worldwide in gynecologic malignancy mainly due to the lack of ultrasensitive diagnosis approaches at its early stage and high cytotoxicity of anticancer drugs to normal cells. In an attempt to overcome the problems, a co-delivery system of folic acid (FA) modified nanoparticles were developed for early diagnosis and to maximize the therapeutic outcome.In the present study, we formulated a diblock copolymer of methoxy poly (ethylene glycol)-b-poly (εcaprolactone)(mPEG-b-PCL) polymer micelles, and FA was further conjugated to endow micelles with active targeted capacity. Then paclitaxel (PTX) and superparamagnetic iron oxide (SPIO) were encapsulated in the core of micelles. The in vitro tumor cell targeting capability of FA-NP/SPIO/PTX and NP/ SPIO/PTX nanoparticles was assessed by confocal laser scanning microscopy (CLSM) with human ovarian cancer (SKOV3 cells) which overexpresses FA receptor. Quantitative analysis showed the amount of intracellular Fe in cells incubated with FA-NP/SPIO/PTX nanoparticles was about 13fold higher than with NP/SPIO/PTX nanoparticles. The imaging contrast capability of FA-NP/ SPIO/PTX nanoparticles as a sensitive MRI probe was evaluated by a 3 T clinical MR imaging scanner. The T 2 -weighted imaging of cells incubated with targeting nanoparticles was found to have more sensitive imaging enhancement effect on the SKOV3 cells than non-targeting nanoparticles. Furthermore, the antitumor efficiency of targeting nanoparticles was approximately 5-fold higher than that of their counterparts, which further affirmed the feasibility of attaining the higher therapeutic efficacy of antitumor drugs while minimizing damage to healthy cells. The targeting nanoparticles exhibited the biphasic release characteristic in vitro. The results indicated that folatemodified nanoparticles could achieve high targeting specificity, high efficiency of delivery drug and excellent imaging enhancement. Therefore, the targeting nanoplatform has good prospects in noninvasively detecting early ovarian tumors, maximizing the therapeutic efficiency and real-time monitoring of therapeutic response, which can make it possible to lengthen patients' survival and ultimately achieve the goal of individualized medicine for ovarian cancer in the near future.

show abstract

“…Anxiety and negative expectations are both significantly associated with worse treatment-related adverse effects, which in turn may trigger the development of conditioned responses to chemotherapy administration (such as anticipatory nausea/vomiting and needle phobia) or initiate vicious cycles of symptom exacerbation after subsequent treatments that diminish quality of life and increase physical and psychosocial distress [8, 9, 19, 26, 29, 46]. High levels of treatment-related distress increase the risk of noncompliance, decreased or delayed dosing, and interruption or discontinuance of chemotherapy [1, 16, 29], which can reduce the likelihood of remission or cure and jeopardize survival [15, 46]. In view of these considerations, early delivery of interventions to improve tolerability of initial chemotherapy sessions is a key to achieving better patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

Effect of virtual reality on time perception in patients receiving chemotherapy

Schneider

Kisby

Flint

2010

Support Care Cancer

165

154

View full text Add to dashboard Cite

Purpose Virtual reality (VR) during chemotherapy has resulted in an elapsed time compression effect, validating the attention diversion capabilities of VR. Using the framework of the pacemaker–accumulator cognitive model of time perception, this study explored the influence of age, gender, state anxiety, fatigue, and cancer diagnosis in predicting the difference between actual time elapsed during receipt of intravenous chemotherapy while immersed in a VR environment versus patient’s retrospective estimates of time elapsed during this treatment. Materials and methods This secondary analysis from three studies yielded a pooled sample of N=137 participants with breast, lung, or colon cancer. Each study employed a crossover design requiring two matched intravenous chemotherapy treatments, with participants randomly assigned to receive VR during one treatment. Regressions modeled the effect of demographic variables, diagnosis, and Piper Fatigue Scale and State Anxiety Inventory scores on the difference between actual and estimated time elapsed during chemotherapy with VR. Results In a forward regression model, three predictors (diagnosis, gender, and anxiety) explained a significant portion of the variability for altered time perception (F=5.06, p=0.0008). Diagnosis was the strongest predictor; individuals with breast and colon cancer perceived time passed more quickly. Conclusions VR is a noninvasive intervention that can make chemotherapy treatments more tolerable. Women with breast cancer are more likely and lung cancer patients less likely to experience altered time perception during VR (a possible indicator of effectiveness for this distraction intervention). Understanding factors that predict responses to interventions can help clinicians tailor coping strategies to meet each patient’s needs.

show abstract

Chemotherapy Dose Density in Early‐Stage Breast Cancer and Non‐Hodgkin's Lymphoma

Cited by 11 publications

References 65 publications

Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events

Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events

Folate modified nanoparticles for targeted co-delivery chemotherapeutic drugs and imaging probes for ovarian cancer

Effect of virtual reality on time perception in patients receiving chemotherapy

Contact Info

Product

Resources

About